Government of Singapore arm and Goldman Sachs have bought shares of Sun Pharma that were offloaded by Daiichi Sankyo through bulk deal on the NSE.
Japanese pharmaceuticals company Daiichi Sankyo on Tuesday completed the sale of its 8.9 per cent stake (or 21.49 crore shares) in Sun Pharmaceuticals, valued at over Rs 22,000 crore,
Of this, 1.26 crore shares were bought by the Government of Singapore and 2.01 crore shares by Aranda Investment Mauritius PTE Ltd, a wholly-owned subsidiary of Temasek Holdings, the investment arm of the Singapore government.
However, the biggest bulk buyer, of 5.12 crore shares, was Goldman Sachs Singapore. The sale was brokered by the investment bank.
The shares were purchased at an average price of Rs 930.16.
The deliverable quantity to traded quantity on Sun Pharma shares was over 81 per cent on Tuesday, suggesting the remaining 60 per cent of shares on sale were purchased through the day.
Foreign institutional investors bought securities worth over Rs 22,567 crore on Tuesday, a definite shift in trend from the previous day when they were net sellers, suggesting high interest in the stock.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.